inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- 1. able to understand and provide informed consent; 2. recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; 3. received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas), \>30 days and \<8 months prior to enrollment ; and, 4. negative (antibody titer \< 0.8u/ml) or low (antibodies detected at titer ≤ 50 u/ml) response to the vaccine at \> 30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- 1. able to understand and provide informed consent; 2. recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; 3. received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas), \>30 days and \<8 months prior to enrollment ; and, 4. negative (antibody titer \< 0.8u/ml) or low (antibodies detected at titer ≤ 50 u/ml) response to the vaccine at \> 30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- able to understand and provide informed consent; recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas), >30 days and <8 months prior to enrollment ; and, negative (antibody titer < 0.8u/ml) or low (antibodies detected at titer ≤ 50 u/ml) response to the vaccine at > 30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- able to understand and provide informed consent; recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas), >30 days and <8 months prior to enrollment ; and, negative (antibody titer < 0.8u/ml) or low (antibodies detected at titer ≤ 50 u/ml) response to the vaccine at > 30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- 1. able to understand and provide informed consent; 2. recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; 3. received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas), >30 days and <8 months prior to enrollment ; and, 4. negative (antibody titer < 0.8u/ml) or low (antibodies detected at titer ≤ 50 u/ml) response to the vaccine at > 30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- 1. able to understand and provide informed consent; 2. recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; 3. received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas), >30 days and <8 months prior to enrollment ; and, 4. negative (antibody titer < 0.8u/ml) or low (antibodies detected at titer ≤ 50 u/ml) response to the vaccine at > 30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- 1. able to understand and provide informed consent; 2. recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; 3. received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas); and 4. no (no antibodies detected) or low (antibodies detected at titer <50 u/ml) response to the vaccine at ≥30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- 1. able to understand and provide informed consent; 2. recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; 3. received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas); and 4. no (no antibodies detected) or low (antibodies detected at titer <50 u/ml) response to the vaccine at ≥30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- able to understand and provide informed consent; recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas); and no (no antibodies detected) or low (antibodies detected at titer <50 u/ml) response to the vaccine at ≥30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.

inclusion criteria: individuals who meet all the following criteria are eligible for enrollment as study participants- able to understand and provide informed consent; recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment; received 2 doses of either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine as specified in the respective food and drug administration emergency use authorization (fda euas); and no (no antibodies detected) or low (antibodies detected at titer <50 u/ml) response to the vaccine at ≥30 days from dose 2 of the moderna covid-19 vaccine or the pfizer biontech vaccine, using the roche elecsys® anti-receptor binding domain (rbd) assay.